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Abstract: Celecoxib is a selective cyclo-oxygenase 2 inhibitor licensed for use in musculoskeletal 
symptoms as well as in primary dysmenorrhea and acute pain. One advantage celecoxib has over 
traditional nonsteroidal anti-inflammatory drugs is that of significantly fewer gastrointestinal 
side-effects associated with its use. Much has been published on the potential cardiovascular and 
cerebrovascular complications of its administration. This review details the available evidence 
to allow prescribers to make informed decisions in the light of potentially conflicting evidence. 
The overall cardiovascular risk is increased with higher doses of celecoxib but is comparable 
with nonselective nonsteroidal anti-inflammatory use. As with all of these drugs, the potential 
cardiovascular and gastrointestinal risks of prescription need to be weighed up against possible 
benefits for each individual patient and discussed with the patients themselves.
Keywords: arthritis, cardiovascular, celecoxib, gastrointestinal, nonsteroidal anti-inflammatory 
drugs, safety
Introduction
Celecoxib (Celebrex®; Pfizer Inc.) was the first selective cyclo-oxygenase (COX) 2 
inhibitor to be used in everyday clinical practice. It is approved for use for musculoskeletal 
symptoms in osteoarthritis (OA), rheumatoid arthritis (RA) and ankylosing 
spondylitis, as well as in the management of primary dysmenorrhea and acute pain. 
The advantages for selective COX2 inhibitor use has been well-documented in the 
literature; similar efficacy to nonsteroidal anti-inflammatory drugs (NSAIDs) but with 
less gastrointestinal (GI) side-effects. Celecoxib was the first of many selective COX2 
inhibitors most of which have now been withdrawn from clinical use (lumiracoxib 
rofecoxib and valdecoxib) because of concerns of serious side-effects. This review will 
discuss the evidence for the potential benefits of celecoxib use as well as scrutinizing 
the studies which detail its possible deleterious effects.
Clinical effectiveness in treating arthritis
Multiple clinical trials have demonstrated that celecoxib has similar efficacy as 
nsNSAIDs in the management of pain and inflammation, both acute and chronic. 
Emery et al in 19991 studied the efficacy of celecoxib in patients with RA. Three 
hundred twenty-six patients received celecoxib 200 mg twice daily and 329 received 
diclofenac, a NSAID, 75 mg twice daily for 24 weeks. There was no documented 
difference between the 2 drugs for physician’s assessment, patient assessment, number 
of swollen or tender joints, visual analogue scale (VAS) pain score, early morning 
stiffness, or C-reactive protein (CRP). The mean number of swollen and tender joints Therapeutics and Clinical Risk Management 2009:5 890
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did however decrease over the course of the study. ACR-20 
response at 24 weeks was scored as 25% in the celecoxib 
group and 22% in the diclofenac group. This paper was one 
of the initial studies to give credence to the use of celecoxib 
where traditional NSAIDs would have been used for the treat-
ment of arthritis symptoms. In the same year a second group2 
undertook a randomized, placebo-controlled, double-blind 
trial with approximately 200 patients in each arm. Placebo 
was compared with naproxen 500 mg twice daily, celecoxib 
100 mg twice daily, 200 mg twice daily, or 400 mg twice 
daily. Celecoxib produced a significant improvement in signs 
and symptoms of RA for all efficacy measures with maximal 
effects by 2 weeks and comparable with the benefits seen with 
naproxen. Withdrawals for treatment failure were lower for 
all active therapy groups than for placebo (P  0.001).
A few years later, Deeks et al3 performed a systematic 
review of the efficacy of celecoxib compared with another 
nonselective (ns) NSAID or placebo. Over 15,000 patients 
with either OA or RA who had received at least 12 weeks 
of therapy were identified. Efficacy was measured by 
the WOMAC score (Western Ontario and McMaster 
Osteoarthritis Index) and tolerability by rates of withdrawal 
for adverse events. Celecoxib and NSAIDs were equally 
effective for all efficacy outcomes. There were far fewer 
withdrawals in those taking celecoxib than other NSAIDs 
for GI side-effects.
A recently published review of celecoxib assessed the 
clinical and cost- effectiveness of selective COX2 inhibitors 
and NSAIDs for OA and RA treatment.4 Forty randomized 
controlled trials involving celecoxib compared to placebo, 
other selective COX2 inhibitors, or nonselective (ns) NSAIDs 
were identified. Compared with nsNSAIDs, celecoxib was 
equally efficacious and of superior GI tolerability. The 
base-case incremental cost per quality adjusted life year 
(QALY) results for celecoxib versus diclofenac was £151,000.
Celecoxib and the upper 
gastrointestinal system
The GI toxicity of traditional NSAIDs is due to the 
nonselective inhibition of both COX1 and COX2 isoenzymes 
involved in prostaglandin synthesis.5 Selective COX2 
inhibitors were developed to suppress prostaglandin 
production by the COX2 enzyme selectively, consequently, 
giving anti-inflammatory and analgesic benefits while 
protecting the gastroprotective activity of COX1. The clinical 
adverse GI effects of NSAIDs are well known. Clinical 
symptoms are poor predictors of actual gastrointestinal 
injury. Anti-inflammatory drug-induced peptic ulcers are 
frequently asymptomatic. Patients taking traditional NSAIDs 
were previously said to be 5 to 7 times more likely to be 
hospitalized for a GI complication than nonusers.6,7
One of the first studies on the potential lesser upper GI 
effects of celecoxib was published in 1999.2 Patients with RA 
were randomized to one of three differing doses of celecoxib 
(100 mg, 200 mg or 400 mg twice daily), naproxen or placebo. 
All doses of celecoxib were seen to have a reduced frequency 
of endoscopic ulcers than naproxen, the comparative NSAID 
in this study. Emery et al1 demonstrated significantly reduced 
reporting of abdominal pain, gastric ulceration and duodenal 
ulceration when celecoxib was compared with diclofenac 
(P  0.05, P  0.001, and P  0.009, respectively).
The celecoxib long-term arthritis safety study (CLASS) 
was a large double-blind randomized controlled trial. Patients 
with OA or RA were randomized to receive celecoxib 
400 mg twice daily (n = 3987), ibuprofen 800 mg 3 times 
daily (n = 1985) or diclofenac 75 mg twice daily (n = 1996).8 
Initial data (at 6 months follow up) suggested that rates 
of symptomatic GI ulcers and ulcer complications were 
significantly lower with celecoxib compared with NSAIDs. 
However, full study results, when made available, showed 
that there was no difference at 1 year. The CLASS study had 
a high-dropout rate at 1 year which made the interpretation 
of these results somewhat difficult.
In 2002, Mamdani et al9 performed a retrospective 
observational cohort study to compare rates of upper GI 
hemorrhage in elderly patients prescribed NSAIDs and selective 
COX2 inhibitors who were previously anti-inflammatory 
naïve. They found no increased short-term risk with celecoxib 
(adjusted rate ratio 1.0, 95% confidence interval [CI] 0.7 to 1.6), 
unlike NSAIDs and rofecoxib. The risk of upper GI hemorrhage 
with celecoxib was similar to that of controls not using NSAIDs. 
Singh et al10 compared the GI side-effects of celecoxib with 
diclofenac and naproxen in a double-blinded, randomized 
clinical trial of over 13,000 patients (SUCCESS-I). Significantly 
more ulcer complications were seen in the NSAID than 
celecoxib group (0.8/1000-person years versus 0.1/1000-person 
years, odds ratio [OR] 7.02, P = 0.008).
van der Linden et al11 performed a nested case-control 
study of a historical cohort of patients in The Netherlands 
to assess the incidence of first hospitalization for GI events 
in patient prescribed traditional NSAIDs and selective 
COX2 inhibitors (incorporating gastric and duodenal 
ulcers, ulceration of GI tract, gastritis, duodenitis, and 
GI hemorrhage). Adjusted OR for any GI with celecoxib 
therapy was 1.36 (95% CI 0.70 to 2.66). When compared 
with celecoxib, unsurprisingly, the risk was much higher with Therapeutics and Clinical Risk Management 2009:5 891
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the traditional NSAIDs, naproxen (OR 3.26, 95% CI 1.59 
to 6.70) and diclofenac (OR 3.50, 95% 1.76 to 6.98).
Management difficulties can arise when patients are 
admitted with a GI bleed but require anti-inflammatory 
management for musculoskeletal symptoms. Chan et al 
published on recurrent ulcer bleeding rates in patients 
subsequently given celecoxib, who were initially admitted 
with upper GI bleeding while on a traditional NSAID for 
arthritis treatment.12 Patients were either given celecoxib 
plus placebo or esomperazole, a proton-pump inhibitor 
(PPI). The combination group had a significantly reduced 
incidence of upper GI bleeding: 0 vs 12%, P = 0.0004, 95% 
CI 4.1 to 13.7.
Potential prevention of colorectal 
malignancies with celecoxib
The APC study investigators investigated the potential 
benefits of celecoxib on reducing colorectal adenomatous 
polyps and cancer.13 This was on the basis that selective COX2 
inhibitors had been shown to reduce the number of colorectal 
adenomas in animals, as well as that the over expression of 
COX2 had been associated with colorectal adenomatous 
polyps and cancer. Patients who had previously had adeno-
mas removed were randomized to placebo, celecoxib 200 mg 
twice daily or 400 mg twice daily. The estimated cumulative 
incidence of detection of adenomas at year 3 was 43.2% in 
the 200 mg twice daily group (risk ratio [RR] 0.67, 95% CI 
0.59 to 0.77, P  0.001) and 37.5% in the 400 mg twice daily 
group (RR 0.55, 95% CI 0.48 to 0.64, P  0.001) compared 
with placebo. For advanced adenomas in the two treatment 
groups the estimated cumulative incidence was 7.8% (RR 
0.43, 95% CI 0.31 to 0.61, P  0.001) and 6.3% (RR 0.34, 
95% CI 0.24 to 0.50, P  0.001) respectively.
In the same issue of the NEJM, the PreSAP trial 
investigators reported their randomized placebo controlled 
trial. They demonstrated that the use of 400 mg celecoxib 
once daily significantly reduced the occurrence of colorectal 
adenomas within the 3 years after a polypectomy (relative 
risk 0.64, 95% CI 0.56 to 0.75 P  0.001).14
Potential hepatic side-effects
A number of individual case reports have been published 
detailing hepatoxicity secondary to celecoxib treatment.15–17 
More impressive however are the published data on larger-
scale investigatory groups such as the CLASS study where 
nearly 4000 patients took celecoxib at 800 mg/day without 
any significant elevation in aminotransferases compared 
with traditional NSAID.8 Importantly, the SUCCESS-1 study 
showed that the occurrence of transaminitis was much lower 
with celecoxib than with nsNSAIDs, 0.5% versus 1.3% 
(P  0.001).10 The FDA and WHO published a case/noncase 
analysis of spontaneous reports of hepatotoxicity of COX2s 
versus nsNSAIDs. The authors concluded that there was 
no increased safety concerns for celecoxib compared with 
NSAIDs, unlike diclofenac and nimesulide.18 While we 
should be alert to the potential development of abnormal 
liver function while a patient is taking celecoxib, the major 
studies do not show any noteworthy trend.
Celecoxib and acute myocardial 
infarction
Concern was initially raised of the potential cardiovascular 
(CV) toxicity of selective COX2 inhibitors and NSAIDs was 
raised by the publication of data from the VIGOR trial by 
Bombardier et al19 The CV risk of rofecoxib at that time was 
explained by being artefactual because of a presumed car-
dioprotective benefit of naproxen. Subsequent observational 
studies proved that this could not be true.20 The first firm 
evidence demonstrating the increased risk of selective COX2 
inhibitors compared with placebo was the APPROVe trial 
in 2004.21 The results of this trial confirmed many previous 
observational studies on the CV risks of rofecoxib and lead 
to the withdrawal of the drug. Subsequently, the APC13 and 
Pre-SAP14 studies showed that at high doses, celecoxib can 
also increase the risk of CV complications when compared 
to placebo.
The risk of high doses of celecoxib was confirmed in 
a pooled analysis published by Solomon et al.22 The data 
from 7950 patients enrolled in 6 placebo-controlled trials of 
celecoxib was analyzed. There was a clear increased risk of 
all CV events including acute myocardial infarction (AMI) 
with increasing doses of celecoxib (P = 0.0005). It should 
be noted that the patients in these studies had conditions 
other than arthritis. Many observational studies have shown 
that the increase in risk is not limited to celecoxib, but 
indeed is present with most nsNSAIDs23 and that the risk 
with celecoxib may be of smaller magnitude than most 
other NSAIDs.24 There are a large number of observational 
studies in publication in which these conclusions are also 
borne out.4,11,25–30
As mentioned previously, a large amount of data related 
to celecoxib and AMI is available from studies investigating 
the potential benefits in colorectal neoplasia prevention. 
The first data were published by Solomon et al in 2005.31 
Deaths from CV causes and nonfatal AMI numbered 27 in 
patients exposed to celecoxib, calculated hazard ratio (HR) Therapeutics and Clinical Risk Management 2009:5 892
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3.4 (nonfatal AMI alone numbered 18). A further paper 
published by Bertagnolli et al13 the following year analyzed 
CV “disorders”, encompassing a variety of conditions 
including AMI, angina, cerebrovascular disease, and circula-
tory collapse. RR in the whole group for low-dose celecoxib 
was 1.5, compared with 1.8 in higher doses.
The much referenced systematic review and meta-analysis 
from McGettigan and Henry24 analyzed the risk of serious CV 
events with selective COX2 inhibitor therapy. They found 
that celecoxib was not associated with an increased risk 
of vascular occlusion (summary RR 1.06, 95% CI 0.91 to 
1.23). This compares with summary RR of 1.33 for low-dose 
rofecoxib (95% CI 1.00 to 1.79), 2.19 for high-dose rofecoxib 
(95% CI 1.64 to 2.91), 1.40 for diclofenac (95% CI 1.16 to 
1.70), 1.07 for ibuprofen (95% CI 0.97 to 1.18), and 0.97 for 
naproxen (95% CI 0.97 to 1.18).
As detailed from the many published works on this topic, 
the data on potential increased cardiovascular risk for patients 
taking celecoxib are inconsistent. It would seem clinically 
appropriate for the decision on prescription to be made on a 
patient by patient basis taking into account the individual’s 
CV history and risk profile, and with regular reviews of 
the need for therapy. While inconsistent, the evidence most 
likely points to an increase in risk of AMI with celecoxib 
compared to placebo when doses of at least 400 mg are 
used. No clinical trials have been able to show an increased 
risk when 200 mg/day or less is used, although this does not 
rule out such an effect in susceptible patients. The increased 
risk does not seem to be out of proportion to the risk seen 
with nsNSAIDs.
Celecoxib and heart failure
Anti-inflammatory drugs can be associated with a degree of 
fluid retention through an increased cortical expression of 
COX2. Mamdani’s population-based retrospective cohort 
study32 assessed nearly 19000 NSAID-naïve patients who 
were commenced on celecoxib. Less than 1% developed 
congestive heart failure (CHF) within 6 months of com-
mencement (identical to nonNSAID control group) and 
approximately 6% developed CHF over a 5-year period (not 
significant compared to the control group).
A population-based retrospective cohort study studied 
2256 patients aged over 66 who were prescribed NSAID, rofecoxib 
or celecoxib after an index admission for CHF.33 Crude event 
rates for recurrent CHF per 100 person-years were calculated 
and showed a difference between selective COX2 inhibi-
tors (celecoxib 27.6, rofecoxib 32.4) and NSAIDs 
(24.4). Within the Colorectal Adenoma Prevention 
trial31 the number of nonfatal heart failure events with 
the placebo group (n = 2, 0.3%) was comparable to the 
events in the celecoxib 200 mg bd group (n = 1, 0.1%). 
A case control study of patients admitted with congestive 
cardiac failure34 identified 25 first admissions in patients 
prescribed celecoxib. Two of these patients had taken less 
than 600 mg celecoxib in the week prior to admission, 
15 had taken between 601 and 1400 mg celecoxib, and 
4 taken greater than 1400 mg. Multivariate analysis and 
comparison with controls showed a weak and statistically 
nonsignificant association between celecoxib use and 
hospitalization for CHF (OR 1.47, 95% CI 0.86 to 2.53, 
P = 0.160) – this was also seen for rofecoxib and other 
traditional NSAIDs.
Potential renal side-effects
The physiological interactions between COX2 and the 
renal system is complex. Increased cortical expression of 
COX2 is seen with sodium depletion, aortic coarctation, 
CHF, loop diuretic therapy and Bartter’s syndrome 
amongst others. COX2 expression is specifically linked to 
the renin-angiotensin system (RAS) and causes activation 
of this pathway. Decreased RAS activity causes increased 
COX2 expression and vice versa. COX2 is known to have 
critical roles at the cortical thick ascending limb of the loop 
of Henle, macula densa and in the medullary interstitium.35 
There is case-report documentation of renal side-effects 
secondary to celecoxib use,17 but much more robust data 
are available from a number of large-scale studies and 
reviews.
A randomized crossover trial of celecoxib with 
naproxen as the comparator looked specifically at renal 
function outcomes in an elderly population.36 A compa-
rable reduction in glomerular filtration rate was seen for 
both naproxen and celecoxib and therefore the selective 
COX2 inhibitor was not felt to be any more nephrotoxic. 
Similarly, the CLASS study did not show any significant 
elevation in serum creatinine in nearly 4000 celecoxib 
users when compared with NSAID users (ibuprofen or 
diclofenac).8 Zhang et al published a large meta-analysis of 
114 randomized, double-blind controlled trials of selective 
COX2 inhibitors, within which 37 celecoxib trial populations 
were identified.37 The RR of developing renal dysfunction 
with celecoxib was 0.61 (95% CI 0.4 to 0.94) compared 
with controls. No between-treatment difference in creatinine 
clearance or serum electrolytes was seen in a double-blind, 
placebo-controlled study of 85 patients assigned to naproxen, 
etoricoxib, or celecoxib.38Therapeutics and Clinical Risk Management 2009:5 893
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As per prescribing guidelines, the use of celecoxib and 
NSAIDs is contra-indicated in patients with pre-existing 
renal impairment. The prescribing physician should remain 
alert to the development of abnormal renal function in a 
patient prescribed celecoxib, but its use is not associated 
with any increased nephrotoxicity compared with traditional 
NSAIDs.
Blood pressure effects of celecoxib
The effects of the addition of celecoxib on blood pressure 
(BP) control in patients on angiotension-converting enzyme 
inhibitors for hypertension has been studied via 24-hour 
ambulatory BP monitoring.39 Doses of celecoxib 200 mg 
twice daily made no difference on the anti-hypertensive 
effect of lisinopril. Wolfe et al have published data on the 
association of NSAID use with hypertension.40 In normo-
tensive and hypertensive patients, there was no increased 
OR of higher documented BP with celecoxib. This was not 
the case for rofecoxib. Zhang’s meta-analysis also failed 
to show any increased RR of hypertension with celecoxib 
therapy: 0.83.37
A number of meta-analyses have scrutinized the potential 
evidence connecting celecoxib with a rise in blood pressure. 
Aw et al published a meta-analysis in 2005 of 19 randomized 
control trials, which included 8 celecoxib trial populations.41 
Weighted mean differences (WMD) of systolic and diastolic 
BPs were calculated. Overall, a disproportionate increase in 
systolic rather than diastolic BP was seen with all nsNSAIDs. 
The overall RR of developing hypertension for celecoxib 
compared with placebo was not statistically significant 
(0.81, 95% CI 0.13 to 5.21). These data on hypertension 
compares well with the only other selective COX2 inhibitor 
still on the market, etoricoxib.
The CRESCENT investigators, lead by Sowers, did not 
show any difference with celecoxib on 24-hour ambulatory 
BP control in known hypertensives.42 However, the proportion 
of patients with controlled blood pressure at baseline who 
developed worsening of BP by week 6 was documented 
as 16% in the celecoxib arm (P = 0.05), indicating that like 
all NSAIDs, BP monitoring is advised whenever treatment is 
initiated with celecoxib. Bertagnolli’s work on the potential 
role in colorectal adenoma prevention of celecoxib docu-
mented some blood pressure data.13 There was no significant 
increased RR of developing hypertension in the cohort and 
aspirin co-prescription made no difference. In contrast, 
Schwartz et al demonstrated a significant increase in ambula-
tory systolic BP with etoricoxib 90 mg once daily compared 
with celecoxib 200 mg twice daily and naproxen 500 mg 
twice daily (P  0.05).38 Additionally, recently published 
data from the MEDAL study documented an increase in 
systolic BP (average rise of 3.4 to 3.6 mmHg) with etoricoxib 
therapy.43
Celecoxib and stroke
Within the Colorectal Adenoma Prevention trial,31 the 
number of nonfatal strokes with the placebo group was 
identical to the events in the celecoxib 200 mg twice daily 
group (n = 3, 0.4%), compared with 5 events (0.7%) in 
the celecoxib 400 mg twice daily group. Solomon et al’s 
cohort study of over 26,000 celecoxib users in the Medicare 
program identified 988 strokes and an adjusted RR of 1.00 
(95% CI 0.92 to 1.09).29
A landmark study from Andersohn and colleagues 
assessed nearly 500,000 patients on the UK GP research 
database between 2000 and 200444 to identify the risk of 
ischemic stroke with NSAID or selective COX2 inhibitor 
use. No increased risk was found with current celecoxib 
use (multivariate OR 1.07). An increased risk was seen with 
rofecoxib and etoricoxib (OR 1.71 and 2.38, respectively). 
As per the AMI data, a dose-dependent effect was seen. 
Celecoxib at 200 mg/day was associated with a multivariate 
OR 0.97 (95% CI 0.71 to 1.32) and 200 mg/day was asso-
ciated with a multivariate OR 1.20 (95% CI 0.46 to 3.11). 
Etoricoxib at 60 mg/day was associated with a much higher 
multivariate OR 2.04 (95% CI 0.87 to 4.80) and 60 mg/day 
was associated with a multivariate OR 3.27 (95% CI 0.59 
to 18.16). It is possible that these differences in stroke rates 
between celecoxib and etoricoxib reflect the differential effect 
on hypertension of these drugs.
Lee et al45 reviewed the impact of celecoxib prescrip-
tion on cerebrovascular disease incidence in patients with 
and without documented coronary artery disease (CAD). 
There was no increased risk of cerebrovascular event in the 
group without CAD prescribed celecoxib (OR 0.97, 95% 
CI 0.68 to 137). However, there was an increased risk of 
events in those with pre-existing CAD prescribed celecoxib 
(OR 1.40, 95% CI 0.96 to 2.03). A recently published study 
based on data from the population-based Rotterdam study  46 
assessed HR for ischemic stroke with NSAID and selective 
COX2 inhibitor prescription. Only 1 event was documented 
in celecoxib users and therefore there was no significant 
outcome.
Nadareishvili et al47 performed a nested case control 
analysis to determine the risk of stroke in patients with RA. 
Two hundred sixty-nine patients with first-ever stroke were 
identified, including 41 in patients with RA. The OR for Therapeutics and Clinical Risk Management 2009:5 894
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ischemic stroke in RA was 2.66 (95% CI 1.24 to 5.70, P = 
0.012). Adjusted for cardiovascular, RA risk factors, and 
other co-variants, ischemic stroke was significantly associated 
with rofecoxib use (OR 3.66, P = 0.27), but not significantly 
with celecoxib (OR 2.65, P = 0.051). A recently published 
retrospective cohort study of over 300,000 Medicaid patients 
in Tennessee over a 5-year period48 documented 4354 
stroke admissions. Of these, 144 were patients who were 
prescribed celecoxib. Compared with nonusers of selective 
COX2 inhibitors or NSAIDs, the adjusted HR for stroke 
was only 1.04 (95% CI 0.87 to 1.23). A slightly higher HR 
of 1.12 (95% CI 0.83 to 1.52) in new users of celecoxib was 
documented.
Effects of co-prescription 
of celecoxib and aspirin
The benefit of aspirin in the primary and secondary preven-
tion of CV events is well established. As the prescription 
rates for aspirin will continue to climb, the number of patients 
potentially prescribed this as well as an anti-inflammatory 
drug will too.
Wilner et al49 published a double-blind, placebo-controlled 
trial of 16 healthy volunteers assigned to celecoxib 400 mg daily 
or placebo for 4 days. Aspirin 325 mg plus celecoxib 200 mg 
or placebo was prescribed on day 5. No significant difference 
in thromboxane inhibition between the 2 groups was noted. 
There was also no significant difference in the effect of aspirin 
on platelet aggregation due to ADP, collagen, or arachidonic 
acid between the groups. The groups summarized that cele-
coxib does not have an effect on the aspirin effects of platelet 
function. This is an important consideration in the selection of 
NSAIDs in patients on low-dose aspirin since, unlike celecoxib, 
several nsNSAIDs have been shown to cause pharmacodynamic 
interference with the anti-platelet effect of aspirin.
The population impact of any possible interaction is 
potentially large. In a sample of the general population 
prescribed selective COX2 inhibitors, analyzed by Cox 
et al50 48% were co-prescribed aspirin, 43% paracetamol, 
and, interestingly, 10% also were prescribed a nonselective 
NSAID. Unsurprisingly, the use of aspirin increased with 
increasing patient age.
Levesque51 documented the RR of first AMI in a cohort 
of over 113,000 elderly patients. Patients prescribed cele-
coxib with or without aspirin were identified. There was no 
significant difference in adjusted RR of AMI in those who 
were or were not prescribed aspirin alongside celecoxib. This 
differs from the low-dose rofecoxib group who showed a 
significantly reduced risk of AMI if prescribed aspirin – the 
same was not true for patients on high-dose rofecoxib. It must 
be pointed out that the actual number of patients who had 
an AMI while on aspirin was small and conclusions drawn 
from this study should be guarded. Rahme et al found that 
the combination of celecoxib and aspirin was less likely 
to be associated with hospitalization for GI events than 
NSAIDs with aspirin (HR 0.62, 95% 0.48 to 0.80).52,53 In fact, 
hospitalization rates for GI events were similar for celecoxib 
plus aspirin as NSAID without aspirin (HR 1.01, 95% CI 0.81 
to 1.25). A limitation of the study was that over-the-counter 
data for aspirin were not available.
Conclusion
Celecoxib continues to be an effective and valuable alternative 
to traditional NSAIDs in the treatment of acute and chronic 
pain. The superior GI tolerability is well-documented and com-
pelling. Data on potential increased CV risk for patients taking 
celecoxib are inconsistent, but do point to a small increase 
risk, especially when higher doses are prescribed. This risk 
is comparable with that of traditional nonselective NSAIDs.
As with all of these drugs, the potential CV and GI risks 
of prescription need to be weighed against possible benefits 
for each individual patient and discussed with the patient. 
If the CV risk increase with celecoxib is small and lower 
than that of most other NSAIDs, the concern would be of 
increasing the complications in a high CV risk patient if they 
were to be prescribed another NSAID. If such a high-risk 
patient must take aspirin, the argument for selective COX2 
inhibitors is stronger as nsNSAIDs may block the effect of 
aspirin. Concomitant PPI use should be considered in these 
patients. As is the case with all anti-inflammatories, the 
prescription of celecoxib for an individual patient should be 
reviewed regularly and the lowest dose used for the shortest 
possible period of time.
Disclosures
The authors declare no conflicts of interest.
References
  1.  Emery P, Zeidler H, Kvien TK, Guslandi M, Naudin R, Stead H, 
et al. Celecoxib versus diclofenac in long-term management of 
rheumatoid arthritis: randomised double-blind comparison. Lancet. 
1999;354(9196):2106–2111.
  2.  Simon LS, Weaver AL, Graham DY, Kivitz AJ, Lipsky PE, Hubbard RC, 
et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib 
in rheumatoid arthritis: a randomized controlled trial. JAMA. 
1999;282(20):1921–1928.
  3.  Deeks JJ, Smith LA, Bradley MD. Efficacy, tolerability, and upper 
gastrointestinal safety of celecoxib for treatment of osteoarthritis and 
rheumatoid arthritis: Systematic review of randomised controlled trials. 
BMJ. 2002;325(7365):619–623.Therapeutics and Clinical Risk Management 2009:5 895
Celecoxib in arthritis Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
  4.  Chen Y-F, Jobanputra P, Barton P, Bryan S, Fry-Smith A, Harris G, et al. 
Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs 
(etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and 
lumiracoxib) for osteoarthritis and rheumatoid arthritis: A systematic 
review and economic evaluation. Health Technol Assess (Rockv). 
2008;12(11):iii–158.
  5.  Meade EA, Smith WL, DeWitt DL. Differential inhibition of 
prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by 
aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem. 
1993;268(9):6610–6614.
  6.  Fries JF, Miller SR, Spitz PW, Williams CA, Hubert HB, Bloch DA. 
Toward an epidemiology of gastropathy associated with nonsteroidal 
antiinflammatory drug use. Gastroenterology. 1989;96(2 Pt 2 Suppl): 
647–659.
  7.  Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of non-
steroidal antiinflammatory drugs. N Engl J Med. 1999;340(24):1888–
1899. [erratum in N Engl J Med. 1999;341(7):548].
  8.  Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, 
Whelton A, et al. Gastrointestinal toxicity with celecoxib vs non-
steroidal anti-inflammatory drugs for osteoarthritis and rheuma-
toid arthritis: the CLASS study: A randomized controlled trial. 
Celecoxib Long-term Arthritis Safety Study. JAMA. 2000;284(10): 
1247–1255.
  9.  Mamdani M, Rochon PA, Juurlink DN, Kopp A, Anderson GM, 
Naglie G, et al. Observational study of upper gastrointestinal 
haemorrhage in elderly patients given selective cyclo-oxygenase-2 
inhibitors or conventional non-steroidal anti-inflammatory drugs. BMJ. 
2002;325(7365):624–627.
10.  Singh G, Fort JG, Goldstein JL, Levy RA, Hanrahan PS, Bello AE, et al. 
Celecoxib versus naproxen and diclofenac in osteoarthritis patients: 
SUCCESS-I Study. Am J Med. 2006;119(3):255–266. [erratum in Am 
J Med. 2006;119(9):801].
11.  van der Linden MW, van der Bij S, Welsing P, Kuipers EJ, Herings 
RMC. The balance between severe cardiovascular and gastrointe-
stinal events among users of selective and non-selective non-steroidal 
anti-inflammatory drugs. Ann Rheum Dis. 2009;68:668–673.
12.  Chan FK, Wong VW, Suen BY, Wu JC, Ching JY, Hung LC, et al. 
Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump 
inhibitor for prevention of recurrent ulcer bleeding in patients 
at very high risk: a double-blind, randomised trial. Lancet. 
2007;369(9573):1621–1626.
13.  Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, 
Kim K, et al. Celecoxib for the prevention of sporadic colorectal 
adenomas. N Engl J Med. 2006;355(9):873–884.
14.  Arber N, Eagle CJ, Spicak J, Racz I, Dite P, Hajer J, et al. Celecoxib 
for the prevention of colorectal adenomatous polyps. N Engl J Med. 
2006;355(9):885–895.
15.  Galan MV , Gordon SC, Silverman AL. Celecoxib-induced cholestatic 
hepatitis. Ann Intern Med. 2001;134(3):254.
16.  Grieco A, Miele L, Giorgi A, Civello IM, Gasbarrini G. Acute 
cholestatic hepatitis associated with celecoxib. Ann Pharmacother. 
2002;36(12):1887–1889.
17.  Tabibian  JH,  Tabibian  N,  Kaufman  DM.  Late-onset 
celecoxib-induced combined hepato-nephrotoxicity. Br J Clin 
Pharmacol. 2008;66(1):150–151.
18.  Sanchez-Matienzo D, Arana A, Castellsague J, Perez-Gutthann S. 
Hepatic disorders in patients treated with COX-2 selective inhibitors or 
nonselective NSAIDs: A case/noncase analysis of spontaneous reports. 
Clin Ther. 2006;28(8):1123–1132.
19.  Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, 
et al. Comparison of upper gastrointestinal toxicity of rofecoxib and 
naproxen in patients with rheumatoid arthritis. VIGOR Study Group. 
N Engl J Med. 2000;343(21):1520–1528.
20.  Ray WA, Stein CM, Hall K, Daugherty JR, Griffin MR. Non-
steroidal anti-inflammatory drugs and risk of serious coronary heart 
disease: an observational cohort study. Lancet. 2002;359(9301): 
118–123.
21.  Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, 
et al. Cardiovascular events associated with rofecoxib in a colorectal 
adenoma chemoprevention trial. N Engl J Med. 2005;352(11): 
1092–1102. [erratum in N Engl J Med. 2006;355(2):221].
22.  Solomon SD, Wittes J, Finn PV , Fowler R, Viner J, Bertagnolli MM, et al. 
Cardiovascular risk of celecoxib in 6 randomized placebo-controlled 
trials: the cross trial safety analysis. Circulation. 2008;117(16): 
2104–2113.
23.  McKellar G, Madhok R, Singh G. The problem with NSAIDs: what 
data to believe? Curr Pain Headache Rep. 2007;11(6):423–427.
24.  McGettigan P, Henry D. Cardiovascular risk and inhibition of 
cyclooxygenase: a systematic review of the observational studies of 
selective and nonselective inhibitors of cyclooxygenase 2. JAMA. 
2006;296(13):1633–1644.
25.  Andersohn F, Suissa S, Garbe E. Use of first- and second-generation 
cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs and risk 
of acute myocardial infarction. Circulation. 2006;113(16):1950–1957.
26.  Gislason GH, Jacobsen S, Rasmussen JN, Rasmussen S, Buch P, 
Friberg J, et al. Risk of death or reinfarction associated with the use of 
selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal 
antiinflammatory drugs after acute myocardial infarction. Circulation. 
2006;113(25):2906–2913.
27.  Graham DJ, Campen D, Hui R, Spence M, Cheetham C, Levy G, 
et al. Risk of acute myocardial infarction and sudden cardiac death in 
patients treated with cyclo-oxygenase 2 selective and non-selective non-
steroidal anti-inflammatory drugs: nested case-control study. Lancet. 
2005;365(9458):475–481.
28.  Helin-Salmivaara A, Virtanen A, Vesalainen R, Gronroos JM, Klaukka T, 
Idanpaan-Heikkila JE, et al. NSAID use and the risk of hospitalization 
for first myocardial infarction in the general population: a nationwide 
case-control study from Finland. Eur Heart J. 27(14):1657–1663.
29.  Solomon DH, Avorn J, Sturmer T, Glynn RJ, Mogun H, Schneeweiss S. 
Cardiovascular outcomes in new users of coxibs and nonsteroidal 
antiinflammatory drugs: high-risk subgroups and time course of risk. 
Arthritis Rheum. 2006;54(5):1378–1389.
30.  Hernandez-Diaz S, Varas-Lorenzo C, Garcia Rodriguez LA. Non-
steroidal antiinflammatory drugs and the risk of acute myocardial 
infarction. Basic Clin Pharmacol Toxicol. 2006;98(3):266–274.
31.  Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, 
Finn P, et al. Cardiovascular risk associated with celecoxib in a 
clinical trial for colorectal adenoma prevention. N Engl J Med. 
2005;352(11):1071–1080.
32.  Mamdani M, Juurlink DN, Lee DS, Rochon PA, Kopp A, Naglie G, et al. 
Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-
inflammatory drugs and congestive heart failure outcomes in elderly 
patients: a population-based cohort study. Lancet. 2004;363(9423): 
1751–1756.
33.  Hudson M, Richard H, Pilote L. Differences in outcomes of patients 
with congestive heart failure prescribed celecoxib, rofecoxib, or 
non-steroidal anti-inflammatory drugs: population based study. BMJ. 
2005;330(7504):1370.
34.  McGettigan P, Han P, Jones L, Whitaker D, Henry D. Selective COX-2 
inhibitors, NSAIDs and congestive heart failure: differences between 
new and recurrent cases. Br J Clin Pharmacol. 2008;65(6):927–934.
35.  Harris CJ, Brater DC. Renal effects of cyclooxygenase-2 selective 
inhibitors. Curr Opin Nephrol Hypertens. 2001;10(5):603–610.
36.  Whelton A, Schulman G, Wallemark C, Drower EJ, Isakson PC, 
Verburg KM, et al. Effects of celecoxib and naproxen on renal function 
in the elderly. Arch Intern Med. 2000;160(10):1465–1470.
37.  Zhang J, Ding EL, Song Y. Adverse effects of cyclooxygenase 2 inhibi-
tors on renal and arrhythmia events: meta-analysis of randomized trials. 
JAMA. 2006;296(13):1619–1632.
38.  Schwartz JI, Thach C, Lasseter KC, Miller J, Hreniuk D, Hilliard DA, 
et al. Effects of etoricoxib and comparator nonsteroidal anti-inflammatory 
drugs on urinary sodium excretion, blood pressure, and other renal 
function indicators in elderly subjects consuming a controlled sodium 
diet. J Clin Pharmacol. 2007;47(12):1521–1531.Therapeutics and Clinical Risk Management 2009:5
Therapeutics and Clinical Risk Management
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/therapeutics-and-clinical-risk-management-journal
Therapeutics and Clinical Risk Management is an international, peer-
reviewed journal of clinical therapeutics and risk management, focusing 
on concise rapid reporting of clinical studies in all therapeutic areas, 
outcomes, safety, and programs for the effective, safe, and sustained 
use of medicines. This journal is indexed on PubMed Central, CAS, 
EMBase, Scopus and the Elsevier Bibliographic databases. The 
manuscript management system is completely online and includes a 
very quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.
896
McKellar and Singh Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
39.  White WB, Kent J, Taylor A, Verburg KM, Lefkowith JB, 
Whelton A. Effects of celecoxib on ambulatory blood pressure in 
hypertensive patients on ACE inhibitors. Hypertension. 2002;39(4): 
929–934.
40.  Wolfe F, Zhao S, Pettitt D. Blood pressure destabilization and 
edema among 8538 users of celecoxib, rofecoxib, and nonselec-
tive nonsteroidal antiinflammatory drugs (NSAID) and nonusers of 
NSAID receiving ordinary clinical care. J Rheumatol. 2004;31(6): 
1143–1151.
41.  Aw TJ, Haas SJ, Liew D, Krum H. Meta-analysis of cyclooxygenase-2 
inhibitors and their effects on blood pressure. Arch Intern Med. 
2005;165(5):490–496.
42.  Sowers JR, White WB, Pitt B, Whelton A, Simon LS, Winer N, 
et al. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal 
anti-inflammatory therapy on 24-hour blood pressure in patients 
with hypertension, osteoarthritis, and type 2 diabetes mellitus. Arch 
Intern Med. 2005;165(2):161–168. [erratum in Arch Intern Med. 
2005;165(5):551].
43.  Krum H, Swergold G, Curtis SP, et al. Factors associated with blood 
pressure changes in patients receiving diclofenac or etoricoxib: results 
from the MEDAL study. J Hypertens. 2009;27(4):886–893.
44.  Andersohn F, Schade R, Suissa S, Garbe E. Cyclooxygenase-2 selective 
nonsteroidal anti-inflammatory drugs and the risk of ischemic stroke: 
a nested case-control study. Stroke. 2006;37(7):1725–1730.
45.  Lee TA, Bartle B, Weiss KB. Impact of NSAIDS on mortality and the 
effect of preexisting coronary artery disease in US veterans. Am J Med. 
2007;120(1):98.e9–e16.
46.  Haag MD, Bos MJ, Hofman A, Koudstaal PJ, Breteler MM, Stricker BH. 
Cyclooxygenase selectivity of nonsteroidal anti-inflammatory drugs 
and risk of stroke. Arch Intern Med. 2008;168(11):1219–1224.
47.  Nadareishvili Z, Michaud K, Hallenbeck JM, Wolfe F. Cardiovascular, 
rheumatologic, and pharmacologic predictors of stroke in patients with 
rheumatoid arthritis: a nested, case-control study. Arthritis Rheum. 
2008;59(8):1090–1096.
48.  Roumie CL, Mitchel EF Jr, Kaltenbach L, Arbogast PG, Gideon P, 
Griffin MR. Nonaspirin NSAIDs, cyclooxygenase 2 inhibitors, and the 
risk for stroke. Stroke. 2008;39(7):2037–2045.
49.  Wilner KD, Rushing M, Walden C, Adler R, Eskra J, Noveck R, et al. 
Celecoxib does not affect the antiplatelet activity of aspirin in healthy 
volunteers. J Clin Pharmacol. 2002;42(9):1027–1030.
50.  Cox ER, Frisse M, Behm A, Fairman KA. Over-the-counter pain reliever 
and aspirin use within a sample of long-term cyclooxygenase 2 users. 
Arch Intern Med. 2004;164(11):1243–1246.
51.  Levesque LE, Brophy JM, Zhang B. The risk for myocardial infarction 
with cyclooxygenase-2 inhibitors: a population study of elderly adults. 
Ann Intern Med. 2005;142(7):481–489.
52.  Rahme E, Nedjar H. Risks and benefits of COX-2 inhibitors vs 
non-selective NSAIDs: does their cardiovascular risk exceed their 
gastrointestinal benefit? A retrospective cohort study. Rheumatology. 
46(3):435–438.
53.  Rahme E, Bardou M, Dasgupta K, Toubouti Y, Ghosn J, Barkun AN. 
Hospitalization for gastrointestinal bleeding associated with non-steroidal 
anti-inflammatory drugs among elderly patients using low-dose aspirin: 
a retrospective cohort study. Rheumatology. 2007;46(2):265–272.